Myelostim

Phase 2Protein / enzyme

IIRCCS San Raffaele

Myelostim is one of 7 small molecule programs targeting Stem Cells. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stem CellsRecruiting

Stem CellsPhase 2

Recruiting

Competition

Competitive Landscape

7 competitors in Stem Cells

#DrugCompanyPhaseTrials

Mozobil

GGenzyme, a Sanofi Company

Phase 2

5 2

Advil

KKenvue Brands

Phase 2

1 3

G-CSF

AArog Pharmaceuticals, Inc.

Phase 1

1 4

Mozobil

NNational Institute of Allergy and Infectious Diseases (NIAID)

Phase 2

1 5

Myelostim

IIRCCS San Raffaele

Phase 2

1 6

Blood

UUniversity Hospital, Lille

Preclinical

1 7

Adipose-Derived Stem Cells

XXuzhou Medical University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Stem Cells1 trial

Combination of Ibuprofen, G-CSF and Plerixafor as Stem Cells Mobilization Regimen in Patients Affected by X-CGD

Recruiting·IIRCCS San Raffaele·Phase 2·NCT03055247·3 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Myelostim. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Myelostim compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Myelostim. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — IRCCS San Raffaele company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: IIRCCS San Raffaele

Myelostim

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Stem Cells1 trial

References

Drug Info

Quick Facts

Related News